Adipotide
Targeted fat-loss peptide that selectively destroys the blood supply to white fat tissue
Clinical Research Score: 2/5 — Evidence is limited to preclinical studies, including a primate obesity study; no human trials have been conducted.
Categories: Weight Loss / Metabolic
What is Adipotide?
Adipotide takes a fundamentally different approach to fat loss than anything else in the peptide world. Most weight-loss compounds either suppress appetite (like the GLP-1s), boost metabolism (like the uncouplers), or shift hormonal balance. Adipotide does none of those things — it simply cuts off the blood supply to white fat tissue, causing the fat cells to be reabsorbed by the body.
The science is genuinely elegant. Fat tissue, like all living tissue, requires a dedicated blood supply to survive. The blood vessels that feed white fat have unique markers on their surface that distinguish them from blood vessels supplying other tissues. Adipotide finds those specific markers, attaches to them, and triggers the targeted destruction of those blood vessels. Without their blood supply, the fat cells shrink and are absorbed. Lean tissue, organs, and other essential structures are untouched because they don't carry the same vascular markers.
In primate studies, obese rhesus monkeys lost roughly 11% of their body weight and 38% of their white fat over a single 4-week cycle, with significant improvements in insulin sensitivity. There's no appetite suppression, no metabolic crash, no muscle loss — the weight loss happens because there's literally less fat tissue.
This is an advanced compound. Kidney function needs to be monitored carefully because the kidneys clear the peptide and can be stressed at higher doses. It's typically used in short cycles (around 28 days) rather than continuously, with breaks between cycles. For people who have struggled with stubborn fat that doesn't respond to other interventions, Adipotide represents one of the most targeted fat-loss tools available.
How Adipotide works
Adipotide is a two-part peptide: one end seeks out a specific protein (prohibitin) that's found on the inner surface of blood vessels supplying white fat tissue but not on other blood vessels. Once it locks on, the other end of the molecule punches holes in the cell's mitochondria, triggering programmed cell death (apoptosis) in that endothelial cell. The blood vessels feeding white fat collapse, and the fat cells they were supplying lose their oxygen and nutrient supply, shrink, and get reabsorbed by the body. Because the targeting is highly specific to white adipose vasculature, lean tissue, organs, and brown fat are largely spared. The result is direct, mechanical fat loss without altering appetite, metabolic rate, or hormonal balance — your body simply has less fat tissue at the end of the cycle.
Scientific overview
Adipotide (also known as FTPP, fat-targeted proapoptotic peptide) is a peptidomimetic conjugate developed at MD Anderson Cancer Center. It consists of a CKGGRAKDC homing motif that binds prohibitin on the endothelial cells lining the vasculature of white adipose tissue, fused to a KLAKLAK pro-apoptotic sequence that disrupts mitochondrial membranes once internalized. By selectively inducing apoptosis in the blood vessels feeding white fat, Adipotide effectively starves adipocytes of their blood supply, leading to fat cell resorption and substantial reductions in adiposity. Preclinical studies in obese rhesus monkeys demonstrated approximately 11% body weight loss and 38% reduction in white adipose tissue over 4 weeks of treatment, with corresponding improvements in insulin sensitivity.
Dosing
- Starting dose: 1 mg per day
- Common dosage range: 1-3 mg per day (typically 28-day cycles)
- Administration: Subcutaneous
- Half-life: ~3-4 hours
- Frequency: 1x daily